India’s Anesiva Loses Adlea, Zingo Painkillers From Market
This article was originally published in PharmAsia News
Executive Summary
A Phase III trial failed to support India-based Anesiva's Adlea (capsaicin) painkiller at the same time the firm said it would withdraw another painkiller, Zingo (lidocaine), from the U.S. market. The twin moves, according to an analyst, endanger the company's financial future. The trial showed Adlea failed to meet the main goal of the trial, Anesiva said. It withdrew Zingo because of problems with the shelf life of the drug caused by manufacturing difficulties, Anesiva said. The company said it still seeks to form a partnership with another firm on both drugs. Resurrecting Zingo would take at least a year and millions of dollars, the analyst said. (Click here for more